Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04858568 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

PROSECO
Start date: March 11, 2021
Phase:
Study type: Observational

This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will collect peripheral blood from patients with lymphoid cancers before and after their COVID-19 vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and T-cell responses to the spike protein. Detailed clinical information will also be collated on about their cancer and treatment.

NCT ID: NCT04858373 Completed - Appetitive Behavior Clinical Trials

Characterizing Emmer Seeds and Flours, and Determining the Glycemic Effects of Emmer Breads

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study characterized emmer seeds, flours, and breads, and investigated the effects of emmer breads on the glycemic response

NCT ID: NCT04858178 Completed - Clinical trials for Spinal Cord Injuries

Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

This study looks to characterize autonomic nervous system dysfunction after spinal cord injury and identify the potential role that transcutaneous spinal cord stimulation may play at altering neuroregulation. The autonomic nervous system plays key parts in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with spinal cord injury typically encounter complications. For both individuals with spinal cord injury and uninjured controls, experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate sympathetic signals. The investigators anticipate that those with autonomic dysfunction after spinal cord injury will exhibit abnormalities in these precise metrics. In both study populations, transcutaneous spinal cord stimulation will be added, testing previously advocated parameters to alter autonomic neuroregulation. In accomplishing this, the investigators hope to give important insights to how the autonomic nervous system works after spinal cord injury and if it's function can be improved utilizing neuromodulation.

NCT ID: NCT04857697 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates whether engineering gut microbiome using probiotics will alter the body's immune system to react to stage I-III breast or lung cancers that can be removed by surgery (operable). Having diverse species of bacteria inside the bowel may help improve the immune system, particularly the ability of the immune system to recognize cancer. Taking probiotics may change the diversity and make up of the bacteria in the bowels, and change how the immune system reacts to breast or lung cancer.

NCT ID: NCT04857606 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Start date: May 24, 2021
Phase: Phase 1
Study type: Interventional

This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).

NCT ID: NCT04857554 Completed - Appetitive Behavior Clinical Trials

Effects of Sugar-free Products With Added Sweeteners on Glycemic Responses

Start date: July 30, 2020
Phase: N/A
Study type: Interventional

This study investigated the effects of three commonly used sugar-free snacks with added sweeteners on glycemic responses

NCT ID: NCT04857437 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Study in Healthy Adults Evaluating PF-07202954

Start date: May 13, 2021
Phase: Phase 1
Study type: Interventional

The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

NCT ID: NCT04857164 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma

NCT ID: NCT04857060 Completed - Palliative Care Clinical Trials

Palliative Care Educator

VIDEO-PCE
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The investigators propose to conduct a stepped wedge cluster randomized trial of an advance care planning (ACP) educator-led intervention among hospitalized patients aged 65 and over, or any patient with Alzheimer's Disease and Related Dementias (ADRD) and their proxy decision-makers in the ward and ICU settings of two major hospitals: Boston Medical Center and North Shore University Hospital in New York. Patient outcomes will be abstracted from electronic health records with Natural Language Processing. The effectiveness of the intervention will be evaluated by comparing the following outcomes among 9,000 hospitalized patients (Aim 1): ACP documentation; preferences for resuscitation; palliative care consults; and, hospice use. The investigators will characterize caregiver-centered outcomes of patients with ADRD, including (Aim 2): (1) knowledge, (2) confidence in future care, (3) communication satisfaction, and (4) decisional certainty in 600 caregivers of patients with ADRD admitted to the hospital. COVID-19 poses a unique dilemma for older Americans and patients with ADRD and their caregivers, who must balance their desire to live against the risk of a lonely and potentially traumatic hospital death. Video decision support is a practical, evidence-based, and innovative approach to assist patients facing such choices. If proven effective, this innovative care model can be immediately deployed across the country to improve the quality of care for millions of Americans.

NCT ID: NCT04856540 Completed - Clinical trials for Cryopyrin Associated Periodic Syndrome

Adult Outcomes of Children With CAPS

CAPS
Start date: September 16, 2021
Phase:
Study type: Observational

The patients included in this study were followed up in the Internal Medicine and Paediatrics Departments of the Lille CHU, the Paediatric Rheumatology and Immunology Department of the Necker Enfant Malade Hospital in Paris and the Paediatric Rheumatology Department and Internal Medicine of the Bicêtre Hospital in Paris. All patients selected presented one of the 3 CAPS clinical phenotypes (CINCA/NOMID, Muckle-Wells or Cold Urticaria). The mutation and the determination of the variant had to be confirmed by genetic analysis. Patient data were collected from their medical records, retrospectively. Data collected concern childhood period from appearance of symptoms, adulthood period, in the last year and patients' way of life and quality of life upon the assessment. In addition, we collected demographic data related to the patients' lifestyle (intoxications, living arrangements, level of education) and we conducted individual telephone interviews lasting 15 minutes to complete a quality of life questionnaire including the SF36 questionnaire. The study aimed to describe the clinical symptoms of patients in adulthood and to assess quality of life. We also wanted to compare the clinical phenotypes of patients according to their genetic variant.